Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 4
2013 4
2014 2
2015 1
2016 2
2017 3
2018 8
2019 3
2020 4
2021 6
2022 2
2023 13
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean joanne hsu (28 results)?
Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy.
Alcantara MB, Tang WS, Wang D, Kaniowski D, Kang E, Dizman N, Chehrazi-Raffle A, Meza L, Zengin Z, Hall J, Hsu J, Egelston C, Moreira D, Horsager A, Pal SK, Kortylewski M. Alcantara MB, et al. Among authors: hsu j. Front Immunol. 2024 Jan 8;14:1274781. doi: 10.3389/fimmu.2023.1274781. eCollection 2023. Front Immunol. 2024. PMID: 38259453 Free PMC article.
Racial and ethnic differences in perceptions of germline or somatic DNA sequencing among patients with advanced prostate, urothelial, or kidney cancer.
Bergerot CD, Philip EJ, Malhotra J, Bergerot PG, Castro DV, Govindarajan A, Salgia S, Salgia M, Salgia N, Hsu J, Meza L, Zengin ZB, Liu S, Chehrazi-Raffle A, Tripathi A, Dorff T, Pal S. Bergerot CD, et al. Among authors: hsu j. J Genet Couns. 2023 Sep 12. doi: 10.1002/jgc4.1786. Online ahead of print. J Genet Couns. 2023. PMID: 37697864
Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy.
Castro DV, Prajapati SR, Feng MI, Chan EH, Lee KO, Paul T, Sehgal I, Patel J, Li X, Zengin ZB, Ebrahimi H, Govindarajan A, Meza L, Mercier BD, Chawla NS, Dizman N, Philip EJ, Hsu J, Bergerot CD, Chehrazi-Raffle A, Rock A, Liu S, Tripathi A, Dorff TB, Pal SK. Castro DV, et al. Among authors: hsu j. BJU Int. 2024 Mar;133(3):297-304. doi: 10.1111/bju.16148. Epub 2023 Sep 1. BJU Int. 2024. PMID: 37548533
Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma.
Dizman N, Govindarajan A, Zengin ZB, Meza L, Tripathi N, Sayegh N, Castro DV, Chan EH, Lee KO, Prajapati S, Feng M, Loo V, Pace M, O'Brien S, Bailey E, Barragan-Carrillo R, Chehrazi-Raffle A, Hsu J, Li X, Agarwal N, Pal SK. Dizman N, et al. Among authors: hsu j. Clin Genitourin Cancer. 2023 Oct;21(5):530-536. doi: 10.1016/j.clgc.2023.06.004. Epub 2023 Jun 25. Clin Genitourin Cancer. 2023. PMID: 37495481
Changes in Perception of Cure Among Patients With Genitourinary Cancers Initiating Immune Checkpoint Inhibitors: A Longitudinal Study.
Bergerot CD, Philip EJ, Govindarajan A, Castro D, Malhotra J, Bergerot P, Salgia S, Salgia M, Salgia N, Hsu J, Meza L, Zengin ZB, Liu S, Chehrazi-Raffle A, Tripathi A, Dorff T, Pal S. Bergerot CD, et al. Among authors: hsu j. Clin Genitourin Cancer. 2023 Dec;21(6):626-630.e3. doi: 10.1016/j.clgc.2023.05.018. Epub 2023 Jun 2. Clin Genitourin Cancer. 2023. PMID: 37391301
Examining Exclusion Criteria in Advanced Prostate Cancer Clinical Trials: An Assessment of recommendations From the American Society Of Clinical Oncology and Friends of Cancer Research.
Ebrahimi H, Castro DV, Feng MI, Prajapati SR, Lee KO, Chan EH, Paul T, Sehgal I, Patel J, Li X, Zengin ZB, Meza L, Mercier BD, Hsu J, Govindarajan A, Chawla N, Dizman N, Bergerot CD, Rock A, Liu S, Tripathi A, Dorff T, Pal SK, Chehrazi-Raffle A. Ebrahimi H, et al. Among authors: hsu j. Clin Genitourin Cancer. 2023 Dec;21(6):e467-e473. doi: 10.1016/j.clgc.2023.05.013. Epub 2023 May 24. Clin Genitourin Cancer. 2023. PMID: 37301665
Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma.
Chehrazi-Raffle A, Muddasani R, Dizman N, Hsu J, Meza L, Zengin ZB, Malhotra J, Chawla N, Dorff T, Contente-Cuomo T, Dinwiddie D, McDonald BR, McDaniel T, Trent JM, Baehner FL, Murtaza M, Pal SK. Chehrazi-Raffle A, et al. Among authors: hsu j. JCO Precis Oncol. 2023 Apr;7:e2200543. doi: 10.1200/PO.22.00543. JCO Precis Oncol. 2023. PMID: 37027813 Free PMC article.
Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis.
Meza L, Zengin Z, Salgia S, Malhotra J, Karczewska E, Dorff T, Tripathi A, Ely J, Kelley E, Mead H, Hsu J, Dizman N, Salgia N, Chawla N, Chehrazi-Raffle A, Muddasani R, Govindarajan A, Rock A, Liu S, Salgia R, Trent J, Altin J, Pal SK. Meza L, et al. Among authors: hsu j. Oncologist. 2023 Sep 7;28(9):e748-e755. doi: 10.1093/oncolo/oyad067. Oncologist. 2023. PMID: 36971500 Free PMC article.
Patients' Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19.
Bergerot CD, Malhotra J, Bergerot P, Philip EJ, Castro DV, Hsu J, Mota ACA, Cardoso de Azeredo A, Neto JNM, Hutson T, Grünwald V, Bex A, Psutka SP, Rini B, Plimack ER, Master V, Albiges L, Choueiri TK, Pal S, Powles T. Bergerot CD, et al. Among authors: hsu j. Oncologist. 2023 Jun 2;28(6):494-500. doi: 10.1093/oncolo/oyad028. Oncologist. 2023. PMID: 36917626 Free PMC article.
43 results